Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

Inclusion Criteria:

1. Diagnosis of systemic AL amyloidosis;

2. Daratumumab, bortezomib, dexamethasone used in 1st line treatment;

3. Life expectancy greater than 12 weeks;

4. HGB ≥70g/L;

5. Blood oxygen saturation >90%;

6. Total bilirubin (TBil) ≤3×upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0×ULN;

7. Informed consent explained to, understood by and signed by the patient.

Exclusion Criteria:

1. Fulfill with the criteria of active multiple myeloma or active lymphoplasmacyticlymphoma.

2. Presence of other tumors which is/are in advanced malignant stage and has/havesystemic metastasis;

3. Severe or persistent infection that cannot be effectively controlled;

4. Presence of severe autoimmune diseases or immunodeficiency disease;

5. Patients with active hepatitis B or hepatitis C ([HBVDNA+] or [HCVRNA+]);

6. Patients with HIV infection or syphilis infection;

7. Any situations that the researchers believe will increase the risks for the subjector affect the results of the study.